Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

@article{Dimopoulos2017CardiacAR,
  title={Cardiac and renal complications of carfilzomib in patients with multiple myeloma.},
  author={Meletios Athanasios Dimopoulos and Maria Roussou and Maria Gavriatopoulou and Erasmia Psimenou and Dimitrios C. Ziogas and Evangelos Eleutherakis-Papaiakovou and Despina Fotiou and Magdalini Migkou and Nikolaos Kanellias and Ioannis Panagiotidis and Argyrios S Ntalianis and Elektra S Papadopoulou and Kimon Stamatelopoulos and Efstathios Manios and Constantinos Pamboukas and S Kontogiannis and Evangelos Terpos and Efstathios Kastritis},
  journal={Blood advances},
  year={2017},
  volume={1 7},
  pages={449-454}
}
Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%) experienced a reversible reduction of left ventricular ejection fraction (LVEF) by ≥20%, an objective measure of cardiac dysfunction. The incidence of LVEF reduction was 5% at 3 months, 8% at 6… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 48 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…